Eye health: Evidence-Based Supplement Guide

One of the 72 people in Avelor with a saved stack holds something taken for eyes. This category is unusual in the product because it contains **the single strongest supplement result in medicine**, and almost everything sold alongside it is unsupported. Telling those apart is the whole job here. The strong result is AREDS2. A large randomised trial tested adding lutein, zeaxanthin and omega-3 to an established supplement formulation in people with **age-related macular degeneration** (PMID 23644932, 22840421). Its long-term follow-up reported that beta-carotene, an ingredient of the original formula, was associated with increased lung cancer risk, while lutein and zeaxanthin were not (PMID 35653117). It also reported that lutein and zeaxanthin had a potentially beneficial association with progression to late macular degeneration. Two things follow, and both matter more than the headline. This evidence is for **people who already have a specific eye disease**, not for general eye health. And it is the rare case where a supplement trial found a **harm** and the formula changed because of it. The rest is thinner and in one case clearly negative. The DREAM randomised trial tested omega-3 for dry eye disease and found that participants **did not have significantly better outcomes than placebo** over a year (PMID 29652551). A systematic review and meta-analysis of computer vision syndrome found no high-certainty evidence for any therapy examined (PMID 35597519). It found low-certainty evidence that oral omega-3 reduces dry eye symptoms in symptomatic computer users, and a further review reports a benefit specifically in screen users (PMID 37026312). For blue light, a Cochrane review of blue-light filtering spectacle lenses found the evidence insufficient to define their effects on visual performance, macular health or sleep (PMID 37593770). A separate review of blue light and sleep reached no firm conclusion (PMID 36051910). Bilberry is the clearest example of a claim that did not survive being checked. A systematic review of placebo-controlled trials of bilberry anthocyanosides for **night vision** did not support the claim it is best known for (PMID 14711439). A later randomised trial reported improvement in some measures of screen-related eye fatigue, which is a different and much smaller claim (PMID 25923485). A supplement combining astaxanthin, lutein and zeaxanthin reported reduced decline in eye-hand coordination after screen work (PMID 36986186). For glaucoma, a review of herbal medicines concludes that larger and longer studies against standard care are needed before any benefit can be claimed (PMID 32607093).

1. **See an optometrist or ophthalmologist first.** Nothing here substitutes for having your eyes examined, and the one strong result applies only to a diagnosed condition. 2. **Do not take an AREDS-type formula unless you have been told you have the condition it was tested in** (PMID 23644932). 3. **If you smoke or used to smoke, avoid beta-carotene formulations** (PMID 35653117). 4. **Treat dry eye as a condition to have assessed**, not one to self-treat with fish oil (PMID 29652551). 5. **Expect nothing from blue-light lenses on current evidence** (PMID 37593770).

Where the research supports a timeframe, the DREAM trial ran for **twelve months** and found no benefit (PMID 29652551). The AREDS2 follow-up reports outcomes over **years**, which is the timescale macular degeneration progresses on (PMID 35653117). The screen-related eye fatigue trials run over **weeks** and measure a different kind of outcome entirely (PMID 25923485).

- **AREDS2's result does not generalise to healthy eyes.** It was conducted in people with age-related macular degeneration or its precursors (PMID 22840421). Selling the formula as general eye support is a population substitution, not a dose question. - **The clearest omega-3 result here is null** (PMID 29652551), and the positive signals are low-certainty and in screen users specifically (PMID 35597519, 37026312). - **Bilberry's night-vision claim was tested and not supported** (PMID 14711439). The later positive work is about screen fatigue, which is not the same claim. - **Blue-light lens evidence is insufficient rather than negative** (PMID 37593770), and the guide says insufficient rather than rounding it either way. - **Nothing here addresses the eye conditions that actually cause sight loss** beyond macular degeneration. Glaucoma, diabetic retinopathy and cataract are managed clinically.

- **Beta-carotene formulations and smoking history do not mix.** The AREDS2 long-term follow-up associated beta-carotene with increased lung cancer risk, which is why lutein and zeaxanthin replaced it (PMID 35653117, 23644932). If you smoke or used to, raise any carotenoid supplement with **a clinician**. - **High-dose vitamin A is specifically discouraged in Stargardt disease** (PMID 35243166). Anyone with an inherited retinal condition should raise supplements with **their ophthalmologist**, not assume eye products are neutral. - **Do not self-treat glaucoma.** Herbal options have not been shown comparable to standard care and the review saying so is explicit about it (PMID 32607093). Glaucoma damage is irreversible, which makes experimenting the expensive choice. - **Sudden vision loss, new floaters or flashes, a curtain across the vision, eye pain with nausea, or sudden double vision are emergencies.** Go to an eye casualty or emergency department, not to a supplement. - **Persistent dry eye deserves assessment** (PMID 29652551). It can accompany autoimmune conditions and medication effects, both of which have treatments.

Resolves **and** has a catalogue key, so it can be interaction-checked: - `avelor:sup:omega-3`, `avelor:sup:omega-3-fish-oil` **Nothing else in this guide resolves at all.** Lutein, zeaxanthin, astaxanthin, bilberry, beta-carotene, zinc and copper have no supplement entity of any type. That means **every ingredient of the AREDS2 formula is unrepresentable**. The single strongest supplement result in medicine, a landmark randomised trial whose findings changed a formulation because of an observed harm, cannot be attached to anything a user can save. It also means the beta-carotene caution cannot fire. A former smoker holding an older-formula eye supplement is the exact person that finding exists to protect, and the product cannot see the ingredient, the formula, or the risk. This is the fourth distinct condition where the gap lands on the guide's own safety point rather than on its recommendations, after thyroid, hair and pregnancy. At this count it is no longer worth describing as bad luck.

| PMID | Title | | --- | --- | | 23644932 | "Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial" | | 22840421 | "The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1)" | | 35653117 | "Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28" | | 29652551 | "n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease" | | 35597519 | "Interventions for the Management of Computer Vision Syndrome: A Systematic Review and Meta-analysis" | | 37026312 | "Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective?" | | 37593770 | "Blue-light filtering spectacle lenses for visual performance, sleep, and macular health in adults" | | 36051910 | "The influence of blue light on sleep, performance and wellbeing in young adults: A systematic review" | | 14711439 | "Anthocyanosides of Vaccinium myrtillus (bilberry) for night vision--a systematic review of placebo-controlled trials" | | 25923485 | "Bilberry extract supplementation for preventing eye fatigue in video display terminal workers" | | 36986186 | "Effects of Astaxanthin, Lutein, and Zeaxanthin on Eye-Hand Coordination and Smooth-Pursuit Eye Movement after Visual Display Terminal Operation in Healthy Subjects: A Randomized, Double-Blind Placebo-Controlled Intergroup Trial" | | 32607093 | "Herbal Medicines in Glaucoma Treatment" | | 35243166 | "Late-onset Stargardt disease" |